kidney issues with semaglutide Recent medical milestones include the **2025 FDA approval** of **Ozempic ( semaglutide)** specifically to slow the progression of chronic disease (CKD) in patients type 2 diabetes. Clinical trials showed a **24% Semaglutide in Diabetic Kidney Disease:

SGLT-2 inhibitors Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are a class of drug that promotes glucose excretion in the urine by inhibiting its reabsorption in the proximal tubule

Therefore, there is a need for alternative approaches for increasing functional -cell mass in patients with diabetes

Multiple studies 17 suggest that inositol can help with ovulation 18 , and it also helps improve the regularity of menstruation

Whole body vibration showed beneficial effect on pain, balance measures and quality of life in painful diabetic peripheral neuropathy: a randomized controlled trial

Patients initiating treatment start on low doses and gradually increase dosage over time